4.6 Article

The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism

Journal

JOURNAL OF VIROLOGY
Volume 95, Issue 4, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01849-20

Keywords

adenoviruses; surface receptor; oncolytic viruses; anticancer therapy

Categories

Funding

  1. Tenovus Cancer Care Ph.D. studentship [PhD2015/L13]
  2. Cancer Research UK Biotherapeutic Program award [C52915/A29104]
  3. Cardiff University School of Medicine Ph.D. studentship
  4. Wellcome Trust ISSF Translational Kickstarter Award [517732]
  5. Cardiff University Research Opportunities Placement (CUROP) award
  6. Cancer Research UK ECMC award [C7838/A25173]
  7. Wellcome Trust ISSF Fellowship [AC1170IF04]
  8. HEFCW

Ask authors/readers for more resources

The human adenovirus phylogenetic tree is diverse, with species D HAdV having low rates of preexisting immunity and potential for therapeutic applications. Studying HAdV-D49 revealed its ability to infect cells through an unidentified receptor, suggesting its potential for therapeutic use.
The human adenovirus (HAdV) phylogenetic tree is diverse, divided across seven species and comprising over 100 individual types. Species D HAdV are rarely isolated with low rates of preexisting immunity, making them appealing for therapeutic applications. Several species D vectors have been developed as vaccines against infectious diseases, where they induce robust immunity in preclinical models and early phase clinical trials. However, many aspects of the basic virology of species D HAdV, including their basic receptor usage and means of cell entry, remain understudied. Here, we investigated HAdV-D49, which previously has been studied for vaccine and vascular gene transfer applications. We generated a pseudotyped HAdV-C5 presenting the HAdV-D49 fiber knob protein (HAdV-C5/D49K). This pseudotyped vector was efficient at infecting cells devoid of all known HAdV receptors, indicating HAdV-D49 uses an unidentified cellular receptor. Conversely, a pseudotyped vector presenting the fiber knob protein of the closely related HAdV-D30 (HAdV-C5/D30K), differing in four amino acids from HAdV-D49, failed to demonstrate the same tropism. These four amino acid changes resulted in a change in isoelectric point of the knob protein, with HAdV-D49K possessing a basic apical region compared to a more acidic region in HAdV-D30K. Structurally and biologically we demonstrate that HAdV-D49 knob protein is unable to engage CD46, while potential interaction with coxsackievirus and adenovirus receptor (CAR) is extremely limited by extension of the DG loop. HAdV-C5/49K efficiently transduced cancer cell lines of pancreatic, breast, lung, esophageal, and ovarian origin, indicating it may have potential for oncolytic virotherapy applications, especially for difficult to transduce tumor types. IMPORTANCE Adenoviruses are powerful tools experimentally and clinically. To maximize efficacy, the development of serotypes with low preexisting levels of immunity in the population is desirable. Consequently, attention has focused on those derived from species D, which have proven robust vaccine platforms. This widespread usage is despite limited knowledge in their basic biology and cellular tropism. We investigated the tropism of HAdV-D49, demonstrating that it uses a novel cell entry mechanism that bypasses all known HAdV receptors. We demonstrate, biologically, that a pseudotyped HAdV-C5/D49K vector efficiently transduces a wide range of cell lines, including those presenting no known adenovirus receptor. Structural investigation suggests that this broad tropism is the result of a highly basic electrostatic surface potential, since a homologous pseudotyped vector with a more acidic surface potential, HAdV-C5/D30K, does not display a similar pantropism. Therefore, HAdV-C5/D49K may form a powerful vector for therapeutic applications capable of infecting difficult to transduce cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers

Mansi Arora, James M. Bogenberger, Amro M. Abdelrahman, Jennifer Yonkus, Roberto Alva-Ruiz, Jennifer L. Leiting, Xianfeng Chen, Pedro Luiz Serrano Uson, Chelsae R. Dumbauld, Alexander T. Baker, Scott Gamb, Jan B. Egan, Yumei Zhou, Bolni Marius Nagalo, Nathalie Meurice, Eeva-Liisa Eskelinen, Marcela A. Salomao, Heidi E. Kosiorek, Esteban Braggio, Michael T. Barrett, Kenneth H. Buetow, Mohamad B. Sonbol, Aaron S. Mansfield, Lewis R. Roberts, Tanios S. Bekaii-Saab, Daniel H. Ahn, Mark J. Truty, Mitesh J. Borad

Summary: The combination of gemcitabine/cisplatin and CDK4/6 inhibitors showed enhanced efficacy, reduced toxicity, and better survival in BTC models. Monotherapy with abemaciclib had modest efficacy due to autophagy-induced resistance, but triplet therapy was able to potentiate efficacy through elimination of the autophagic flux. Abemaciclib also potentiated sensitization to gemcitabine through reduction of ribonucleotide reductase catalytic subunit M1.

HEPATOLOGY (2022)

Article Biochemistry & Molecular Biology

Structure-Guided Engineering of a Family IV Cold-Adapted Esterase Expands Its Substrate Range

Nehad Noby, Rachel L. Johnson, Jonathan D. Tyzack, Amira M. Embaby, Hesham Saeed, Ahmed Hussein, Sherine N. Khattab, Pierre J. Rizkallah, D. Dafydd Jones

Summary: The study on cold active esterase EstN7 reveals that its substrate range is limited but can be broadened through mutations, providing new insights for enzyme engineering.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Development of a low-seroprevalence, avb6 integrin-selective virotherapy based on human adenovirus type 10

Emily A. Bates, James A. Davies, Jana Vanova, Davor Nestic, Valerie S. Meniel, Sarah Koushyar, Tabitha G. Cunliffe, Rosie M. Mundy, Elise Moses, Hanni K. Uusi-Kerttula, Alexander T. Baker, David K. Cole, Dragomira Majhen, Pierre J. Rizkallah, Toby Phesse, John D. Chester, Alan L. Parker

Summary: Oncolytic virotherapies based on human adenoviruses show great clinical potential. Incorporating a peptide that selectively targets alpha v beta 6 integrin, the HAdV-D10 serotype vector can effectively target alpha v beta 6-positive tumor cells. Structural and biological studies show that HAdV-D10 has weak interactions with adenoviral receptors and does not engage blood coagulation factor X, reducing off-target hepatice sequestration. In vitro and in vivo experiments demonstrate that HAdV-D10.A20 selectively kills cancer cells and has significant potential for clinical translation.

MOLECULAR THERAPY-ONCOLYTICS (2022)

Article Biochemistry & Molecular Biology

Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope

Garry Dolton, Cristina Rius, Md Samiul Hasan, Aaron Wall, Barbara Szomolay, Enas Behiry, Thomas Whalley, Joel Southgate, Anna Fuller, Theo Morin, Katie Topley, Li Rong Tan, Philip J. R. Goulder, Owen B. Spiller, Pierre J. Rizkallah, Lucy C. Jones, Thomas R. Connor, Andrew K. Sewell

Summary: This study examined the CD8 T cell response against a specific epitope of the Spike glycoprotein of SARS-CoV-2 and found that a specific mutation was not recognized by the majority of HLA A*02(+) convalescent patients and vaccinated individuals. This highlights the potential problem of viral escape at prevalent T cell epitopes restricted by high frequency HLAs and suggests the inclusion of multiple viral proteins in next generation vaccines. Monitoring T cell escape in new SARS-CoV-2 variants is crucial.
Article Gastroenterology & Hepatology

Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers

Bolni Marius Nagalo, Yumei Zhou, Emilien J. Loeuillard, Chelsae Dumbauld, Oumar Barro, Alexander T. Baker, Mansi Arora, James M. Bogenberger, Natalie Meurice, Joachim Petit, Pedro Luiz Serrano Uson, Faaiq Asiam, Elizabeth Raupach, Musa Gabere, Alexei Basnakian, Camila C. Simoes, Martin J. Cannon, Steven R. Post, Kenneth Buetow, Jean Christopher Chamcheu, Michael T. Barrett, Dan G. Duda, Bertram Jacobs, Richard Vile, Michael A. Barry, Lewis R. Roberts, Sumera Llyas, Mitesh J. Borad

Summary: This study demonstrates that wild-type Morreton virus has potential therapeutic effects on cholangiocarcinoma and hepatocellular carcinoma in vitro models. It can induce immune responses and lead to tumor regression. These findings support further development and clinical translation of Morreton virus as an oncolytic virotherapy platform.

HEPATOLOGY (2023)

Article Biotechnology & Applied Microbiology

Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?

Emma A. A. Swift, Steven M. M. Pollard, Alan L. L. Parker

Summary: Advances in gene therapy, cancer genomics, and immunotherapy have provided more strategies for targeting human cancers using viral vectors. Improving the construction of viral vectors and selecting therapeutic payloads can achieve more precise treatment effects and overcome the challenge of delivering genes to the entire population of cancer cells. It is important to use advanced human cellular models for screening and evaluating novel candidates.

HUMAN GENE THERAPY (2022)

Article Biochemical Research Methods

Pseudotyping Bacteriophage P2 Tail Fibers to Extend the Host Range for Biomedical Applications br

Tabitha G. Cunliffe, Alan L. Parker, Alfonso Jaramillo

Summary: Bacteriophages offer a powerful potential treatment against antibiotic-resistant bacterial infections. Developing novel antibiotics is costly and time-consuming, while bacteria can quickly develop resistance. In contrast, phages can selectively kill pathogenic bacteria and adapt through mutation to regain infectivity.

ACS SYNTHETIC BIOLOGY (2022)

Article Food Science & Technology

The Crystal Structure of Bacillus thuringiensis Tpp80Aa1 and Its Interaction with Galactose-Containing Glycolipids

Hannah L. Best, Lainey J. Williamson, Magdalena Lipka-Lloyd, Helen Waller-Evans, Emyr Lloyd-Evans, Pierre J. Rizkallah, Colin Berry

Summary: Tpp80Aa1 from Bacillus thuringiensis is a toxin protein that shows activity against Culex mosquitoes, as well as larvae of Anopheles gambiae and Aedes aegypti mosquitoes. The crystal structure of Tpp80Aa1 reveals its two domains, resembling ricin B lectin and aerolysin family, and its binding to the midgut of mosquitoes. The interaction with galactose-containing glycolipids and galactose is crucial for its insecticidal action.

TOXINS (2022)

Article Virology

Engineering Adenoviral Vectors with Improved GBM Selectivity

Emily A. Bates, Charlotte Lovatt, Alice R. Plein, James A. Davies, Florian A. Siebzehnrubl, Alan L. Parker

Summary: Glioblastoma (GBM) is a common and aggressive adult brain cancer with a low survival rate. Adenovirus-based gene therapy shows potential as an alternative treatment for GBM. By pseudotyping an HAdV-C5-based platform, we demonstrate that adenoviral entry receptors CAR, CD46, and DSG2 effectively transduce GBM cells. However, the presence of these receptors on healthy cells raises concerns about off-target effects and therapeutic gene expression in non-transformed cells.

VIRUSES-BASEL (2023)

Article Biochemistry & Molecular Biology

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

Garry Dolton, Cristina Rius, Aaron Wall, Barbara Szomolay, Valentina Bianchi, Sarah A. E. Galloway, Md Samiul Hasan, Theo Morin, Marine E. Caillaud, Hannah L. Thomas, Sarah Theaker, Li Rong Tan, Anna Fuller, Katie Topley, Mateusz Legut, Meriem Attaf, Jade R. Hopkins, Enas Behiry, Joanna Zabkiewicz, Caroline Alvares, Angharad Lloyd, Amber Rogers, Peter Henley, Christopher Fegan, Oliver Ottmann, Stephen Man, Michael D. Crowther, Marco Donia, Inge Marie Svane, David K. Cole, Paul E. Brown, Pierre Rizkallah, Andrew K. Sewell

Summary: Tumor-infiltrating lymphocyte therapy can activate T cells of the immune system to target and eliminate solid cancers. Through the use of combinatorial peptide libraries and a proteomic database, the antigen specificities of persistent cancer-specific T cell receptors (TCRs) were identified after successful therapy for stage IV malignant melanoma. These TCRs were capable of targeting multiple tumor types through specific epitopes, and the atomic structures revealed the importance of a shared recognition motif. The ability of these multi-epitope targeting T cells to recognize cancer cells surpasses the recognition of individual epitopes, making them promising candidates for future immunotherapies.
Article Cell Biology

Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+T cell immunity

Yuan Chen, Georgina H. Mason, D. Oliver Scourfield, Alexander Greenshields-Watson, Tracey A. Haigh, Andrew K. Sewell, Heather M. Long, Awen M. Gallimore, Pierre Rizkallah, Bruce J. MacLachlan, Andrew Godkin

Summary: CD4+ T cells recognize a diverse range of SARS-CoV-2 peptide epitopes, contributing to immune memory and limiting COVID-19 disease. The immunogenicity of these peptides does not correlate with their binding affinity to HLA-DR1. X-ray crystallographic structures of six epitopes bound to HLA-DR1 reveal the molecular impact of viral variant mutations on epitope presentation. Omicron variant escapes immune recognition through mutations in TCR-facing epitope positions and a single amino acid substitution that alters the peptide-HLA structure.

CELL REPORTS (2023)

Review Oncology

Oncolytic Viruses and Immune Checkpoint Inhibitors: The Hot New Power Couple

Charlotte Lovatt, Alan L. Parker

Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their efficacy is limited to patients with significant lymphocyte infiltration. Oncolytic viruses (OVs) have shown promise in selectively killing tumor cells and inducing immunogenic cell death, making them a potential modality for combination therapy to overcome the limitations of ICIs. By increasing immune cell infiltration and inducing anti-tumor immunity, OVs can change the cold tumor microenvironment associated with poor response to ICIs, rendering patients more susceptible to these therapies.

CANCERS (2023)

Article Multidisciplinary Sciences

Article Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation

Hannah E. Preston, Rebecca Bayliss, Nigel Temperton, Martin Mayora Neto, Jason Brewer, Alan L. Parker

Summary: Infectious viral particles in bioaerosols generated during laparoscopic surgery pose a significant risk of infection for staff and patients. The use of devices that can capture and inactivate viral particles, such as electrostatic precipitation (EP), can prevent nosocomial viral spread.

ISCIENCE (2023)

Article Oncology

Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy

Pedro Luiz Serrano Uson Junior, Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H. Ahn, Jason S. Starr, Jeremy C. Jones, Hani Babiker, Samantha R. Inabinett, Natasha Wylie, Ashton W. R. Boyle, Tanios S. Bekaii-Saab, Gregory J. Gores, Rory Smoot, Michael Barrett, Bolni Nagalo, Nathalie Meurice, Natalie Elliott, Joachim Petit, Yumei Zhou, Mansi Arora, Chelsae Dumbauld, Oumar Barro, Alexander Baker, James Bogenberger, Kenneth Buetow, Aaron Mansfield, Kabir Mody, Mitesh J. Borad

Summary: This study aimed to evaluate the prognostic value of pretreatment circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based chemotherapy. The results showed that DCAF > 3% was associated with worse overall survival (OS). Stratifying DCAF into quartiles, DCAF > 10% was significantly related to worse progression-free survival (PFS) and OS. Each 1% increase in ctDNA was associated with a decrease in survival probabilities.

JCO PRECISION ONCOLOGY (2022)

No Data Available